Cyteir Therapeutics(CYT) - 2023 Q1 - Quarterly Report

Financial Performance - For the three months ended March 31, 2023, total operating expenses were $13.4 million, a decrease of $0.7 million from $14.1 million in the same period of 2022[89]. - The net loss for the three months ended March 31, 2023 was $12.5 million, an improvement of $1.6 million compared to a net loss of $14.1 million for the same period in 2022[89]. - Net cash used in operating activities for Q1 2023 was $10.2 million, a decrease of $2.0 million compared to $12.2 million in Q1 2022[100]. - The company reported a decrease in net loss of $1.6 million due to reduced research and development expenses[105]. Research and Development - Research and development expenses for the three months ended March 31, 2023 were $9.3 million, down from $10.1 million in the prior year, primarily due to decreased costs in external research activities[90]. - CYT-0851, the company's investigational drug, showed preliminary clinical activity in a small cohort of patients with advanced ovarian cancer, with one confirmed partial response observed[73]. - Enrollment in the CYT-0851 and capecitabine combination cohort is ongoing, with initial data expected to be disclosed in mid-2023[73]. - The company suspended enrollment in the CYT-0851 phase 2 monotherapy cohort due to insufficient activity observed with the drug alone[74]. - The company anticipates continued operating losses and negative cash flows as it progresses with research and development activities for CYT-0851[76]. - The company anticipates significant operating losses as it advances CYT-0851 through clinical development and seeks regulatory approval[96]. - The company expects to incur significant commercialization expenses if regulatory approval for CYT-0851 is obtained[96]. Cash and Financing - As of March 31, 2023, the company had cash and cash equivalents of $137.2 million, expected to fund operations into 2026[78]. - The company has raised approximately $141.0 million from the sale of redeemable convertible preferred stock and $136.1 million in net proceeds from its IPO as of March 31, 2023[94]. - Net cash provided by financing activities for Q1 2023 was $0.1 million, primarily from common stock issuance and stock options exercise[102]. - As of March 31, 2023, the company had cash, cash equivalents, and restricted cash totaling $137.5 million[110]. - The company had no debt outstanding as of March 31, 2023, thus not exposed to interest rate risk related to debt[111]. Operating Expenses - General and administrative expenses increased to $4.1 million for the three months ended March 31, 2023, compared to $4.0 million in the same period of 2022, driven by a rise in personnel-related costs[91]. - Cash flows from investing activities for Q1 2023 were $0.2 million, attributed to the sale of property and equipment[99]. Company Classification - The company is classified as an "emerging growth company" under the JOBS Act, allowing for certain reporting exemptions[106].